Physician profile
Mark A Pierce
NPI 1053388561
$246,115.81
in general payments reported to CMS, 2019-2025
22 companies · $8,348 in 2025
The $8,348 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $8,504 · 2021: $45K · 2022: $73K · 2023: $29K · 2024: $40K · 2025: $8,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Travel and Lodging: $11K · Food and Beverage: $2,058 · Consulting Fee: $1,750 · Education: $55.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,043.75 |
| Travel and Lodging | $10,546.01 |
| Food and Beverage | $2,058.41 |
| Consulting Fee | $1,750.00 |
| Education | $55.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181,313.64 | 2021-2025 | |
| Allergan, INC. | $46,021.42 | 2019-2021 | |
| Melinta Therapeutics, LLC | $17,652.70 | 2019-2023 | Kimyrsa, Orbactiv |
| Insmed, INC. | $295.96 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $166.32 | 2019-2020 | |
| Kci USA, INC. | $93.53 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $81.84 | 2019 | |
| Angiodynamics, INC. | $75.35 | 2019 | |
| Paratek Pharmaceuticals, INC. | $66.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.53 | 2024-2025 | |
| Tetraphase Pharmaceuticals, INC. | $53.69 | 2019 | |
| Vifor Pharma, INC. | $34.85 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $28.50 | 2019 | |
| Corcept Therapeutics | $24.81 | 2019-2020 | |
| Heartflow, INC. | $22.75 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.55 | 2024 | Xarelto |
| Ferring Pharmaceuticals INC. | $20.88 | 2022 | |
| Mylan Specialty L.P. | $17.22 | 2019 | |
| Janssen Biotech, INC. | $16.54 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $13.27 | 2020 | |
| Biosense Webster, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.